Artigo Acesso aberto Revisado por pares

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

2009; The Japanese Society of Internal Medicine; Volume: 48; Issue: 9 Linguagem: Inglês

10.2169/internalmedicine.48.1650

ISSN

1349-7235

Autores

Yuji Minegishi, K. Takenaka, Hideki Mizutani, Junko Sudoh, Rintaro Noro, Tetsuya Okano, Arata Azuma, Akinobu Yoshimura, Masahiro Ando, Eitaka Tsuboi, Shoji Kudoh, Akihiko Gemma,

Tópico(s)

Lung Cancer Treatments and Mutations

Resumo

Objective and Methods Idiopathic interstitial pneumonias (IIPs) frequently occur in association with lung cancer. However, there is no consensus on the best treatment of acute exacerbation of IIP in lung cancer patients (LC with IIP), including those with iatrogenic acute lung injury resulting from cancer treatments. We aimed to identify an appropriate strategy for treatment of this condition. We analyzed clinical features of 120 LC with IIP, retrospectively. Results The incidence of acute exacerbation related to anticancer treatment was 22.7%; when the incidence was examined separately for patients receiving chemotherapy or the best supportive care, the incidence was 20.0% and 31.3%, respectively. Additional investigations should be directed to finding suitable regimens for treatment of LC with IIP and the selection of appropriate patients with LC with IIP for chemotherapy. The incidence of acute exacerbation caused by combination regimens of carboplatin + paclitaxel or a platinum agent + etoposide was significantly lower than that of other regimens (0% vs. 18%, respectively; p=0.025, Fisher's Exact Test). Patients with high levels of C-reactive protein before chemotherapy had a significantly higher risk of developing acute exacerbation (odds ratio 5.60, p=0.028). Conclusion There was no evidence that anticancer treatment, including chemotherapy, should be avoided in LC with IIP. To establish an appropriate cancer treatment for LC with IIP, a prospective clinical study should be performed to evaluate various treatment modalities in a larger patient population.

Referência(s)
Altmetric
PlumX